The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction‐associated steatotic liver disease
European Journal of Clinical Investigation · 2024
DOI: 10.1111/eci.14224 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Ina Bergheim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Endotoxins, Gastrointestinal Microbiome, Obesity. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Austrian Science Fund, Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Background
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a leading cause of end‐stage liver disease associated with increased mortality and cardiovascular disease. Obesity and diabetes are the most important risk factors of MASLD. It is well‐established that obesity‐associated insulin resistance leads to a situation of tissue lipotoxicity characterized by an accumulation of excess fat in non‐fat tissues such as the liver, promoting the development of MASLD, and its progression into metabolic dysfunction‐associated steatohepatitis.
Methods
Here, we aimed to review the impact of disrupted intestinal permeability, antimicrobial proteins and bacterial endotoxin in the development and progression of MASLD. Results and Conclusion Recent studies demonstrated that obesity‐ and obesogenic diets‐associated alterations of intestinal microbiota along with the disruption of intestinal barrier integrity, the alteration in antimicrobial proteins and, in consequence, an enhanced translocation of bacterial endotoxin into bloodstream might contribute to this pathological process through to impacting liver metabolism and inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria.
- Nutrition, Eumetabolism and Health Group, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), Girona, Spain.
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
- Department of Medicine, Universitat de Girona, Girona, Spain.
ORCID-Profile: José María Moreno-Navarrete
Förderung
- Austrian Science Fund
- Ministerio de Ciencia e Innovación
Zitieren
APA
Bergheim, I., & Moreno-Navarrete, J. M. (2024). The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction‐associated steatotic liver disease. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14224
Vancouver
Bergheim I, Moreno-Navarrete JM. The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction‐associated steatotic liver disease. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14224
BibTeX
@article{Bergheim2024,
author = {Bergheim, Ina and Moreno-Navarrete, José María},
title = {The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction‐associated steatotic liver disease},
journal = {European Journal of Clinical Investigation},
year = {2024},
doi = {10.1111/eci.14224}
}
EUVIMED